Meeting Details and Voting Process

The 33rd AGM will be held on September 21, 2026 at 3:00 PM via video conferencing only. E-voting will be available from September 17-20, 2026, with cut-off date of September 14, 2026 for shareholder eligibility. The meeting will consider adoption of financial statements, declaration of final dividend, re-appointment of directors, and appointment of cost auditor.

Financial Performance Highlights FY 2025-26

Bajaj Healthcare reported mixed financial results with revenue from operations growing 12.6% to ₹611.03 crore from ₹542.60 crore in FY25. However, net profit declined significantly by 60% to ₹157.66 crore from ₹394.96 crore in FY25, primarily impacted by:

  • Discontinued operations loss of ₹55.44 crore from divestment of Tarapur and Dahej units
  • Exceptional item reversal of ₹332.47 crore related to technical know-how transfer arrangement
  • One-time exceptional loss of ₹33.25 crore affecting PAT which declined 50.4% to ₹21.31 crore

EBITDA grew 9.9% to ₹111.95 crore while EBITDA margin decreased 45 bps to 18.32%. The company maintained strong balance sheet with debt-equity ratio improving to 0.47 times and net worth increasing 14.3% to ₹533.00 crore.

Corporate Actions and Strategic Developments

The Board recommended final dividend of ₹1.50 per share (30%) subject to shareholder approval. The company completed preferential allotment of 20,79,409 shares at ₹338 per share, raising ₹70.28 crore through warrant conversion.

Significant strategic developments include:

  • Acquisition of Genrx Pharmaceuticals Private Limited (in liquidation) for ₹1,085 lakhs, with NCLT application pending
  • Continued divestment of disposal group comprising units at Tarapur and land at Dahej
  • Maintenance of IND A-/Stable credit rating for long-term and IND A2+ for short-term
  • Export contribution of approximately 31% of total turnover with R&D expenditure of ₹13.15 crore (2.2% of revenue)

Regulatory Compliance and Governance

The company has complied with all applicable statutory requirements under Companies Act, 2013 and SEBI regulations. The financial statements comply with Indian Accounting Standards (Ind AS) and received clean audit opinion. CSR obligation for FY26 was ₹94.17 lakhs with actual expenditure of ₹94.46 lakhs. All regulatory disclosures and governance requirements have been properly followed for the AGM and financial reporting.